Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Core Insights - The interim analysis of the Reliance II Phase 3 study for REL-1017 indicated that the study is unlikely to meet its primary efficacy endpoint with statistical significance, although no new safety concerns were identified [1][2] - Relmada Therapeutics will evaluate the full dataset to determine the next steps for the REL-1017 program while continuing to advance the Phase 1 study of REL-P11 for metabolic disease [2] - As of September 30, 2024, Relmada has approximately $54.1 million in cash and cash equivalents, indicating a strong capital position [1] Company Overview - Relmada Therapeutics is a late-stage biotechnology company focused on diseases of the central nervous system (CNS) and metabolic disorders [5] - The company is committed to making a difference in the lives of patients and their families through innovative treatments [5] Product Information - REL-1017 is a novel NMDA receptor channel blocker that targets hyperactive channels while maintaining physiological glutamatergic neurotransmission [3] - REL-P11 is an investigational agent for metabolic disease, with potential applications identified through the acquisition of a psilocybin derivatives program [4]